Soguimap Sarl Pharmaceutical Import Profile — Guinea (DGFT 2022–2026)

Name: Soguimap Sarl Pharmaceutical Import Records from India — 3 Products, $446.3K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Soguimap Sarl — Pharmaceutical Importer Profile (2026) | 3 Products, $446.3K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Soguimap Sarl?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Unilink Pharma Private Limited	$2.1M	189	95.0%
Aura Inc	$111.9K	28	5.0%

Soguimap Sarl sources from 2 verified Indian suppliers across 145 distinct formulations. The sourcing is highly concentrated — Unilink Pharma Private Limited accounts for 95.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Soguimap Sarl Import?

Formulation	Value	Ships
Unimoxi capsules(amoxicillin	$251.3K	6
Benzoic acid and salicylic acid	$106.0K	3
Miconazole nitrate cream 30g -19910	$105.0K	3
Primaderm cream - 9390	$103.8K	3
Artesunate injection 60MG 7500 aihi	$102.5K	3
Silden -50 sildenafil citiate BP eq to	$102.5K	3
Multivitamin syrup -4895	$102.4K	3

What Products Does Soguimap Sarl Import?

Top Products by Import Value

1Miconazole$150.0K 2Salicylic$150.0K 3Sulfadoxine$146.3K

Soguimap Sarl Therapeutic Categories — 3 Specializations

Soguimap Sarl imports across 3 therapeutic categories, with Antifungals (33.6%), Combination Drugs (33.6%), Antimalarial & Antiparasitic (32.8%) representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Antifungals

1 products · 33.6% · $150.0K

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Miconazole	Antifungals	$150.0K	3	0.8%	2
2	Salicylic	Combination Drugs	$150.0K	3	0.9%	4

Key Metrics

Total Import Value$446.3K

Products3

Shipments10

Categories3

CountryGuinea

#1 Rankings0

Indian Suppliers2

Formulations145

Top Categories

Antifungals33.6%

Combination Drugs33.6%

Last updated: March 28, 2026

Soguimap Sarl — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Soguimap Sarl is a prominent pharmaceutical wholesaler and distributor based in Conakry, Guinea. With over 20 years of experience, the company has been dedicated to supplying the Guinean population with quality medications at affordable prices. Their mission centers on enhancing public health by providing certified medicines through a reliable and efficient distribution network.

The company operates as a grossiste répartiteur en pharmacie, which translates to a pharmaceutical wholesaler-distributor. This role involves sourcing, storing, and distributing pharmaceutical products to various healthcare providers across Guinea. Soguimap Sarl emphasizes quality, reliability, integrity, innovation, and social responsibility in its operations, aiming to improve accessibility to healthcare products nationwide.

2Distribution Network

Soguimap Sarl's distribution network is strategically located in Conakry, the capital city of Guinea, facilitating efficient access to the country's primary urban centers. The company's facilities are equipped with modern and secure storage infrastructures, ensuring optimal preservation of pharmaceutical products. Their logistics system is designed for rapid and precise delivery, adhering to health standards and maintaining product integrity throughout the distribution process.

Supplier Relationship Intelligence — Soguimap Sarl

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Soguimap Sarl's sourcing strategy exhibits a high degree of concentration, primarily importing finished pharmaceutical formulations from two Indian suppliers: Unilink Pharma Private Limited and Aura Inc. Unilink Pharma Private Limited accounts for 95% of the shipments, while Aura Inc. contributes 5%. This concentration suggests a strategic choice to maintain strong, reliable partnerships with established suppliers, ensuring consistent product quality and supply. However, such dependency also poses risks; any disruption with these suppliers could significantly impact Soguimap Sarl's ability to meet domestic demand. The stability of these relationships is crucial for the company's operational continuity.

2Supply Chain Resilience

Soguimap Sarl's supply chain resilience is closely tied to its reliance on two primary Indian suppliers. The company's import data indicates a focus on a limited range of pharmaceutical formulations, which may limit its ability to diversify sourcing in response to supply chain disruptions. Additionally, the concentration of shipments from a single supplier could expose the company to risks associated with geopolitical issues, regulatory changes, or logistical challenges in the supplier's country. Ensuring compliance with international quality standards, such as WHO GMP, is essential for maintaining product integrity and meeting regulatory requirements in Guinea.

3Strategic Implications

The concentrated sourcing pattern of Soguimap Sarl positions the company to benefit from strong, established relationships with its Indian suppliers, potentially leading to favorable terms and consistent product availability. For Indian exporters, this presents an opportunity to strengthen partnerships with Soguimap Sarl by ensuring reliable supply and compliance with international quality standards. However, the limited supplier base also indicates a potential vulnerability; Indian exporters seeking to enter the Guinean market should consider diversifying their supplier base to mitigate risks associated with over-reliance on a single source.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Guinea — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Guinea

1Regulatory Authority & Framework

In Guinea, the National Directorate of Medicines and Pharmacies (Direction Nationale du Médicament et des Pharmacies, DNMP) is the primary regulatory authority overseeing pharmaceutical imports, marketing authorizations, and the enforcement of health regulations. The DNMP is responsible for ensuring that imported pharmaceutical products meet the country's health and safety standards. Additionally, the National Ethics Committee for Health Research (Comité National d'Éthique pour la Recherche en Santé, CNERS) plays a role in reviewing health research protocols, which may intersect with pharmaceutical importation processes.

2Import Licensing & GMP

Importers in Guinea are required to obtain formal import authorization, known as Demande Déscriptive d’Importation (DDI), from the Ministry of Commerce for quantities exceeding 12 million GNF (approximately USD 1,250). This process involves submitting a descriptive import application prior to the opening of a virtual transactions folder. Regarding Good Manufacturing Practice (GMP) certifications, Guinea recognizes international standards such as WHO GMP, EU GMP, and PIC/S. Importers must ensure that their suppliers hold valid GMP certificates to comply with regulatory requirements.

3Quality & Labeling

Imported pharmaceutical products in Guinea must undergo batch testing to verify their quality and safety. Stability requirements are enforced to ensure that medications maintain their efficacy throughout their shelf life. Labeling must be in French, the official language of Guinea, and should include essential information such as dosage instructions, expiration dates, and storage conditions. Serialization mandates may be implemented to enhance traceability and prevent counterfeit products from entering the market.

4Recent Regulatory Changes

Between 2024 and 2026, Guinea has updated its regulatory framework to enhance the efficiency and transparency of pharmaceutical imports. The renaming of the National Directorate of Pharmacy and Medicine to the National Directorate of Medicines and Pharmacies reflects a broader focus on pharmaceutical oversight. Additionally, the requirement for ethics approval from the CNERS before submitting drug import license applications to the DNMP indicates a more integrated approach to health research and pharmaceutical regulation.

TransData Nexus Research · Guinea regulatory databasesMar 2026

Seller's Guide — How to Become a Supplier to Soguimap Sarl

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Guinean market by partnering with Soguimap Sarl. The company's established distribution network and focus on high-demand therapeutic areas present avenues for expanding product offerings. Potential gaps in Soguimap Sarl's current sourcing include the need for additional suppliers to mitigate risks associated with over-reliance on a limited number of sources. Indian exporters can explore these opportunities by ensuring compliance with Guinea's regulatory requirements and aligning their product portfolios with the therapeutic needs of the Guinean population.

2Requirements & Qualifications

Indian exporters aiming to supply Soguimap Sarl and the Guinean market must ensure that their products comply with international quality standards, such as WHO GMP, EU GMP, or PIC/S certifications. Importers are required to obtain formal import authorization from the Ministry of Commerce for quantities exceeding 12 million GNF. Additionally, products must meet Guinea's labeling requirements, including French language labeling and adherence to batch testing and stability standards. Ensuring these qualifications will facilitate smoother market entry and regulatory compliance.

3How to Approach

To establish a partnership with Soguimap Sarl, Indian exporters should initiate contact by providing detailed product information, including quality certifications and compliance with international standards. Participating in tenders and responding to requests for proposals can demonstrate commitment and reliability. Developing a clear regulatory filing strategy, including obtaining necessary import authorizations and ensuring compliance with Guinea's import requirements, is essential. Setting realistic timelines for product registration and distribution will help in building a successful and sustainable business relationship.

TransData Nexus Research · Industry procurement practicesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Soguimap Sarl identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Soguimap Sarl's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 10 individual customs records matching Soguimap Sarl.
5.Supplier Verification: Soguimap Sarl sources from 2 verified Indian suppliers across 145 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

3 Products Tracked

3 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Soguimap Sarl

Soguimap Sarl — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Soguimap Sarl?

What Formulations Does Soguimap Sarl Import?

What Products Does Soguimap Sarl Import?

Top Products by Import Value

Soguimap Sarl Therapeutic Categories — 3 Specializations

Import Portfolio — Top 3 by Import Value

Key Metrics

Top Categories

Soguimap Sarl — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Soguimap Sarl

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Guinea — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Soguimap Sarl — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Soguimap Sarl

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Soguimap Sarl

What products does Soguimap Sarl import from India?

Who supplies pharmaceuticals to Soguimap Sarl from India?

What is Soguimap Sarl's total pharmaceutical import value?

What therapeutic categories does Soguimap Sarl focus on?

Get Full Soguimap Sarl Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology